Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?

Infliximab, a chimeric monoclonal anti‐TNFα antibody, has been found to increase the risk of serious infections compared with the TNF receptor fusion protein etanercept in some studies. It is unclear whether the risk varies by patient characteristics. We conducted a study to address this question.

[1]  Jeffrey R Curtis,et al.  Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. , 2011, JAMA.

[2]  Jeffrey R Curtis,et al.  Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems , 2011, Pharmacoepidemiology and drug safety.

[3]  C. Spettell,et al.  The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents , 2011, Annals of the rheumatic diseases.

[4]  Pengxiang Li,et al.  Impact of the medicare modernization act of 2003 on utilization and spending for medicare part B–covered biologics in rheumatoid arthritis , 2010, Arthritis care & research.

[5]  J. Allison,et al.  Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. , 2009, Journal of clinical epidemiology.

[6]  J. Listing,et al.  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. , 2009, JAMA.

[7]  P. Sarzi-Puttini,et al.  Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. , 2009, Autoimmunity reviews.

[8]  Sengwee Toh,et al.  Causal Inference from Longitudinal Studies with Baseline Randomization , 2008, The international journal of biostatistics.

[9]  W. Dixon,et al.  The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis , 2008, Current opinion in rheumatology.

[10]  K. Saag,et al.  Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. , 2007, Arthritis and rheumatism.

[11]  A. Silman,et al.  The British Society for Rheumatology Biologics Register. Ann Rheum Dis 2005;64 Suppl 4:iv42–3 , 2022 .

[12]  John Chan,et al.  Differences in Reactivation of Tuberculosis Induced from Anti-TNF Treatments Are Based on Bioavailability in Granulomatous Tissue , 2007, PLoS Comput. Biol..

[13]  M. Hudson,et al.  Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. , 2007, Rheumatology.

[14]  S. Schneeweiss,et al.  Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. , 2007, Journal of clinical epidemiology.

[15]  J. Allison,et al.  Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. , 2007, Arthritis and rheumatism.

[16]  L. Jacobsson,et al.  Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists , 2007, Annals of the rheumatic diseases.

[17]  M. Dougados,et al.  Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. , 2006, Rheumatology.

[18]  F. Wolfe,et al.  Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. , 2006, Rheumatology.

[19]  A. Silman,et al.  Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. , 2006, Arthritis and rheumatism.

[20]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[21]  Frederick Wolfe,et al.  Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. , 2006, Arthritis and rheumatism.

[22]  F. Breedveld,et al.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.

[23]  Matthias Schneider,et al.  Infections in patients with rheumatoid arthritis treated with biologic agents. , 2005, Arthritis and rheumatism.

[24]  S. Ehlers,et al.  Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. , 2005, Seminars in arthritis and rheumatism.

[25]  J. Robins,et al.  A Structural Approach to Selection Bias , 2004, Epidemiology.

[26]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[27]  R S Wallis,et al.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  S. Gabriel,et al.  Predictors of infection in rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[29]  Richard W. Martin,et al.  Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. , 2002, Arthritis and rheumatism.

[30]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.

[31]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[32]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[33]  C. González,et al.  Proportion of community-acquired pneumonia cases attributable to tobacco smoking. , 1999, Chest.

[34]  D. Furst,et al.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. , 1999, Annals of internal medicine.

[35]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[36]  C. Sherman,et al.  The health consequences of cigarette smoking. Pulmonary diseases. , 1992, The Medical clinics of North America.

[37]  N. Rigotti,et al.  The health consequences of cigarette smoking and the internist's role in smoking cessation. , 1988, Advances in internal medicine.

[38]  J. Phair,et al.  Ageing and infection. , 1988, Ciba Foundation symposium.

[39]  D. Rubin,et al.  Reducing Bias in Observational Studies Using Subclassification on the Propensity Score , 1984 .

[40]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[41]  I D Gardner,et al.  The effect of aging on susceptibility to infection. , 1980, Reviews of infectious diseases.

[42]  R. Prentice.  Use of the logistic model in retrospective studies. , 1976, Biometrics.